accountprop open coronary arteries and the Quill wound-closure device. Taxus was a huge success for Angiotech and partner Boston Scientific until concerns emerged that drug-coated stents carry a higher risk of rare instances of potentially fatal blood clots....
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Angiotech creditors accept restructuring plan
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account